Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Hoffmann-La Roche
Age
50–any
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Part 1, Part 2 and Part 3
Willing to allow AH collection
Part 1 and Part 2
Choroidal neovascularization (CNV) exclusively due to age-related macular degeneration (AMD)
Anti-vascular endothelial growth factor (VEGF) or anti-VEGF/Angiopoietin-2 (Ang-2) IVT treatment-naïve, or pre-treated with anti-VEGF or anti-VEGF/Ang-2 no less than two months prior to Day 1
Sufficiently clear ocular media and adequate pupillary dilatation to allow for analysis and grading by the central reading center of fundus photography (FP), fluorescein angiography (FA), fundus autofluorescence (FAF), and spectral domain optical coherence tomography (SD-OCT) images
Decreased BCVA attributable primarily to nAMD, with BCVA letter score of 78 to 34 letters (inclusive) on ETDRS-like charts at screening. In case both eyes of a participant are eligible, the eye with the lower BCVA score should become the study eye
Part 3
CNV exclusively due to AMD
Diagnosis of nAMD within 36 months prior to the screening visit
Previous treatment with at least one IVT anti-VEGF or anti-VEGF/Ang-2 administrations IVT for nAMD. The last IVT administration must have occurred at least 21 days prior to the screening visit
Demonstrated response to prior IVT anti-VEGF or anti-VEGF/Ang-2 treatment since diagnosis
Availability of historical VA data prior to the first anti-VEGF or anti-VEGF/Ang-2 treatment for nAMD
Sufficiently clear ocular media and adequate pupillary dilatation to allow for analysis and grading
Decreased BCVA attributable primarily to nAMD with letter score of 78 to 34 letters (inclusive) or better on ETDRS-like charts
You may not be if
History of vitrectomy surgery, submacular surgery, other intraocular surgery, or any planned surgical intervention during the study period
Cataract surgery without complications within three months preceding the screening visit or planned during the study period
Aphakia or absence of the posterior capsule. Previous violation of the posterior capsule is also an exclusion criterion, unless it occurred as a result of yttrium-aluminum garnet laser posterior capsulotomy in association with prior, posterior chamber intraocular lens implantation
Prior macular treatment with verteporfin, external beam radiation therapy, transpupillary thermotherapy, or any type of laser photocoagulation
Prior treatment with IVT corticosteroids or implant (e.g., triamcinolone, ozurdex, iluvien)
Subretinal hemorrhage \>50% of the total lesion area and/or involving the fovea
Subfoveal fibrosis or subfoveal atrophy
Retinal pigment epithelial tear involving the macula
History of vitreous hemorrhage, rhegmatogenous retinal detachment, glaucoma-filtering surgery, tube shunts, or microinvasive glaucoma surgery, and corneal transplant
History of rhegmatogenous retinal tears or peripheral retinal breaks within three months prior to the screening visit
Actual or history of myopia \>-8 diopters
Uncontrolled ocular hypertension or glaucoma (defined as intraocular pressure \[IOP\] \>25 millimeters of mercury (mm Hg) or a cup to disc ratio \>0.8, despite treatment with antiglaucoma medication) and any such condition the Investigator determines may require a glaucoma-filtering surgery during a participant's participation in the study
Concurrent intraocular conditions (e.g., cataract, diabetic retinopathy, epiretinal membrane with traction, macular hole) that, in the opinion of the Investigator, could either: require medical or surgical intervention during the study period to prevent or treat visual loss that might result from that condition; or likely contribute to loss of BCVA over the study period if allowed to progress untreated; or preclude any visual improvement due to substantial structural damage
Concurrent conjunctival, Tenon's capsule, and/or scleral condition in the supero-temporal quadrant of the eye (e.g., scarring, thinning, mass) that may affect the implantation, subsequent tissue coverage, and refill-exchange procedure of the PD implant
Prior treatment with any medication for geographic atrophy (GA) during the last 3 months prior to screening
Prior treatment with any anti-VEGF-C or anti-VEGF-D inhibitors
BCVA letter score using ETDRS charts of \< 34 letters
Treatment with IVT anti-VEGF or anti-VEGF/Ang-2 agents within one week prior to Day 1 (concurrent treatment with SUSVIMO\^TM in the fellow eye is not exclusionary)
CNV due to causes other than nAMD, such as ocular histoplasmosis, trauma, pathological myopia, angioid streaks, choroidal rupture, uveitis or central serous chorioretinopathy
Prior participation in a clinical trial involving anti-VEGF drugs within six months prior to the screening visit, other than ranibizumab, aflibercept, or faricimab including approved biosimilars
Active intraocular inflammation (grade trace or above), infectious conjunctivitis, keratitis, scleritis, or endophthalmitis
History of uveitis, including history of any intraocular inflammation following intravitreal therapy
